Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

Journal of Clinical Psychopharmacology

Volumn 17, Issue 4, 1997, Pages 284-291

  Alderman, Jeffrey ^a   Preskorn, Sheldon H ^b   Greenblatt, David J ^c   Harrison, Wilma ^a   Penenberg, Darryl ^a   Allison, Janet ^d   Chung, Menger ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d South Florida Bioavailability Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL PAIN; ADULT; ANXIETY NEUROSIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; DYSURIA; EPISTAXIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STEADY STATE; ULTRAVIOLET SPECTROPHOTOMETRY; VOMITING;

1-NAPHTHYLAMINE; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; CROSS-OVER STUDIES; DESIPRAMINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SERTRALINE;

EID: 0030791275     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199708000-00008     Document Type: Article

References (33)

1. Aranow RB, Hudson JI, Pope HG, Grady TA, Laage TA, Bell IR, Cole JO. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989;146:911-3.
2. Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48:303-7.
3. Cavanaugh SA. Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics 1990;31:273-6.
4. Westermeyer J. Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 1991;31:388-92.
5. Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990;147:532.
6. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
7. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
8. Brøsen K. Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord J Psychiatry 1993;47[suppl 30]: 21-6.
9. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatx JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
10. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome CYP2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1991;32:262-5.
11. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
12. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993;54[suppl 9]:14-34.
13. Ghose K. The pharmacokinetics of paroxetine in elderly depressed patients. Acta Psychiatr Scand 1989;80[suppl 350]: 87-8.
14. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Bussman BD, Greb WH. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80[suppl 350]:60-75.
15. Sindrup SH, BrÌsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine. Clin Pharmacol Ther 1992;51:288-95.
16. Sindrup SH, BrÌsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
17. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
18. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
19. Kenney JT, Orsulak PJ, Kolodner RM, Burton ME. Determination of serum desipramine and 2-hydroxydesipramine for pharmacokinetic applications by HPLC with ultraviolet detection. Clin Chem 1989;35:2134-6.
20. Tremaine LM, Joerg EA. Automated gas chromatographic-electron capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989;496:423-9.
21. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
22. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450-3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29[suppl 1]:33-43.
23. Tulloch IF, Johnson AM. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 1992;53[suppl 2]:7-12.
24. Preskorn SH, DeVane CL. Drug-drug interactions [letter]. J Clin Psychiatry 1996;57:223-7.
25. Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996;59:189-96.
26. Ohmori S, Takeda S, Tadaaki R, Kiuchi M, Kanakubo Y, Kitada M. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull 1993;16:571-5.
27. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, Greb WH. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80[suppl 350]:60-75.
28. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimale BJ. Drug inter-action between sertraline and desipramine and imipramine. J Clin Pharmacol 1994;34:1009.
29. Zussman BD, Davis CC, Fowles SE, Kumar R, Lang U, Wargenau M, Sourgens H. Sertraline like other SSRIs is a significant inhibitor of desipramine metabolism in vivo. Presentation to the British Pharmacological Society, December 16, 1994.
30. Spina E, Birgersson C, von Bahr C, Ericsson O, Mellstrom B, Steiner E. Phenotypic consistency in hydroxylation of desmethyl-imipramine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36:677-82.
31. Ohmori S, Takeda S, Rikihisa T, Kiuchi M, Kauakubo Y, Kitada M. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull 1993;16:571-5.
32. Walle T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993;341:967-8.
33. Ahmed I, Dagincourt PG, Miller LG, Shader RI. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993;38:62-3.